

# CENTER FOR DRUG EVALUATION AND RESEARCH

## Approval Package for:

***APPLICATION NUMBER:***

**125387Orig1s060**

***Trade Name:*** EYLEA

***Generic or Proper Name:*** Aflibercept

***Sponsor:*** Regeneron Inc.

***Approval Date:*** August 12, 2019

***Indication:*** EYLEA is indicated for the treatment of patients with:

- Neovascular (Wet) Age-Related Macular Degeneration (AMD)
- Macular Edema Following Retinal Vein Occlusion (RVO)
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)

# CENTER FOR DRUG EVALUATION AND RESEARCH

## 125387Orig1s060

### CONTENTS

#### Reviews / Information Included in this NDA Review.

|   |          |
|---|----------|
| <b>Approval Letter</b>                                  | <b>X</b> |
| <b>Other Action Letters</b>                             | <b>X</b> |
| <b>Labeling</b>   | <b>X</b> |
| <b>REMS</b>   |          |
| <b>Summary Review</b>                                   |          |
| <b>Officer/Employee List</b>                            |          |
| <b>Office Director Memo</b>                             |          |
| <b>Cross Discipline Team Leader Review</b>              |          |
| <b>Medical Review(s)</b>                                | <b>X</b> |
| <b>Chemistry Review(s)</b>                              |          |
| <b>Environmental Assessment</b>                         |          |
| <b>Pharmacology Review(s)</b>                           |          |
| <b>Statistical Review(s)</b>                            |          |
| <b>Microbiology / Virology Review(s)</b>                |          |
| <b>Clinical Pharmacology/Biopharmaceutics Review(s)</b> |          |
| <b>Other Reviews</b>                                    |          |
| <b>Risk Assessment and Risk Mitigation Review(s)</b>    |          |
| <b>Proprietary Name Review(s)</b>                       |          |
| <b>Administrative/Correspondence Document(s)</b>        |          |

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**125387Orig1s060**

**APPROVAL LETTER**



BLA 125387/S-060

**APPROVAL LETTER**

Regeneron Pharmaceuticals, Inc.  
Attention: Candace Drumma  
Senior Manager Cmc Regulatory Affairs  
81 Columbia Turnpike, Bldg 85  
Rensselaer, NY 12144

Dear Ms. Drumma:

Please refer to your Supplemental Biologics License Application (sBLA) dated and received April 12, 2019, and your amendments, submitted under section 351(a) of the Public Health Service Act for Eylea (afibercept) injection, 2 mg/0.05 mL.

We acknowledge receipt of your amendment dated April 12, 2019, which constituted a complete response to our October 15, 2018, action letter.

This Prior Approval supplemental biologics license application provides for the addition of a new sterile 2 mg/0.05 mL single-dose pre-filled syringe (PFS) presentation for afibercept drug product. The PFS is filled at (b) (4)

sterilized blister pack ( (b) (4)

(b) (4)

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the prescribing information) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

**U.S. Food & Drug Administration**  
Silver Spring, MD 20993  
[www.fda.gov](http://www.fda.gov)

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

### **CARTON AND IMMEDIATE CONTAINER LABELS**

Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels submitted on October 9, 2018 and trade carton labeling submitted on July 24, 2019 as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (May 2015, Revision 3)*. For administrative purposes, designate this submission "**Product Correspondence – Final Printed Carton and Container Labels for approved BLA 125387/S-060.**" Approval of this submission by FDA is not required before the labeling is used.

This information will be included in your biologics license application file.

If you have any questions, call Andrew Shiber, Regulatory Business Process Manager, at (301) 796 - 4798.

Sincerely,

*{See appended electronic signature page}*

Kathleen A. Clouse, Ph.D.  
Director  
Division of Biotechnology Review and Research I  
Office of Biotechnology Products  
Office of Pharmaceutical Quality  
Center for Drug Evaluation and Research

Enclosure(s):

Content of Labeling  
Carton and Container Labeling

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.